Video content above is prompted by the following:
What key infrastructure and procedural steps should health systems take before administering amyloid-targeting therapies, such as ensuring access to infusion centers, updating workflow, and training existing staff or hiring new staff (for example, a neuroradiologist)?- How do you discuss the risk-benefit profile of the amyloid-targeting therapies with patients and their caregivers, including adverse event considerations, adherence to treatment, travel to the infusion center, etc?